Navigation Links
Arthrosurface Raises $4 Million of Preferred Equity Financing
Date:2/28/2008

FRANKLIN, Ma., Feb. 28 /PRNewswire-FirstCall/ -- Arthrosurface, Inc. (http://www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, has announced that it has raised approximately $4 million in its latest Preferred Stock Series F equity financing. Funded by Boston Millennia Partners and private investors, to date, the company has raised approximately $31 million of equity capital. "The Series F funding is earmarked to support our new product launches, expansion of the company's direct field sales team and to provide ongoing working capital," said Steve Ek, COO. "We now have greater resources to provide for the people and working capital to support the continued growth of the business."

Arthrosurface is entering its fourth year of commercial launch with approximately 7,000 devices implanted by more than 2,000 surgeon users in the various joint applications of the HemiCAP(R) system. Last year, US implant sales were up 55% with strong growth across all key product lines. In particular, sales of the company's first US knee device, the Patello-Femoral HemiCAP(R), grew 237% year on year. "We have found that within the first year of clinical launch, implanting surgeons closely monitor patient progress and, once they have confirmed positive results, sales begin to rise significantly. An excellent example of this was our great toe product. Cases went from a few hundred in the first year to thousands within two years. We expect similar adoption with the release of our new products," commented company president Steve Tallarida.

The company's HemiCAP(R) systems consist of a range of contoured articular prosthetics and instrumentation intended for the repair of significant lesions and cartilage damage in the major joints. Arthrosurface continues to grow its line of shoulder, great toe, patello-femoral and hip products in the US. These same products are sold in Europe in additi
'/>"/>

SOURCE Arthrosurface, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
2. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
3. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
4. Primera Biosystems Raises $21 Million in Series B Private Round
5. Cellectar, Inc. Raises $13 Million in Private Offering
6. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
7. Anesiva Raises $45 Million in Common Stock Offering
8. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
9. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
10. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
11. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... ZIONA, Israel , September 2, 2015 ... BVXV) today announced the intent of the National Institute of ... Institutes of Health (NIH) within the Department of Health and ... to be held in the United States ... use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q is ... commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion video ... too quickly to process with the naked eye. , Slow motion sequences ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... (NASDAQ: IDIX ), a biopharmaceutical company engaged ... treatment of human viral diseases, today announced the advancement ... IDX719: NS5A Program Idenix announced today ... the Company,s NS5A inhibitor, IDX719. The first part of ...
... FRANCISCO, January 9, 2012 SFJ Pharma ... announced today that it has entered into a collaborative ... 3 clinical trial in Asia of Pfizer,s investigational agent ... risk of recurrent renal cell carcinoma (RCC) following nephrectomy. ...
... SQNM ), a life sciences company providing innovative ... performance and accomplishments, as well as preliminary activities and goals ... Initial 2011 Performance Results , Total revenue ... , Over 21,000 total prenatal and retinal diagnostic tests were ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 3Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 4
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ... Arabia Biomedical Sensors Market - Growth, Trends & Forecasts ... The Saudi Arabia Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... , August 24, 2015 The consulting ... ,s largest biometrics manufacturer DERMALOG and its customized solutions and ... African Biometrics Company of the Year Award". DERMALOG is particularly ... .   -Cross reference: Picture is available ... - On Thursday evening, in South ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... panobinostat is able to target and destroy triple negative ... Central,s open access journal Breast Cancer Research . ... that panobinostat was able to destroy breast cancer cells ... of breast cancers are found at diagnosis to be ...
... N.Y. -- A pioneering study to gauge the toxicity of ... be safe over a one-year period, a hopeful outcome for ... cancer through nanomedicine. , The research, which will appear on ... the first to test the safety of quantum dots in ...
... The rate at which the rabies virus evolves in ... hosts, according to researchers at the University of Georgia, the ... Leuven in Belgium. Their study, published May 17 in the ... location was the most accurate predictor of the viral rate ...
Cached Biology News:Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2Good news for nanomedicine: Quantum dots appear safe in pioneering study on primates 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
...
... Building on the ease of use and flexibility of ... Biosciences introduces the BDTM LSR II. The BD ... before in a benchtop analyzer. Free up your ... a UV laser to the BD LSR II. The ...
Biology Products: